Low Dose Lung Radiotherapy to Treat COVID-19 Pneumonia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

2 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-11-25

Study Completion Date

2022-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to document the feasibility and tolerability of low dose thoracic radiotherapy in patients with WHO level 5 COVID 19 infections.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Low Dose Pulmonary Irradiation in Patients With COVID-19 Infection of Bad Prognosis

NCT04414293

COVID Pneumonia, Viral

UNKNOWN NA

Best Supportive Care With or Without Low Dose Whole Lung Radiation Therapy for the Treatment of COVID-19

NCT04433949

Pneumonia Severe Acute Respiratory Syndrome Symptomatic COVID-19 Infection Laboratory-Confirmed

UNKNOWN PHASE3

Low-Dose Radiation Therapy for Severe COVID-19 Pneumonia

NCT05694962

COVID-19 Pneumonia

UNKNOWN PHASE2

Low Dose Radiotherapy for COVID-19 Pneumonitis

NCT04420390

Covid19

UNKNOWN NA

Low Dose Radiotherapy in COVID-19 Pneumonia

NCT04390412

COVID SARS (Severe Acute Respiratory Syndrome)

UNKNOWN PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Subjects will be identified following admission to hospital who test positive for COVID-19 infection. They will then be informed and consented, and eligibility confirmed and registered to study. Following this the first, sentinel patient, will be treated with 0.5Gy dose radiotherapy to cover the lungs, with heterogeneity correction. A further 0.5Gy dose can be repeated within 96 hours. There shall then be a 7 day gap prior to recruiting patient 2. The remaining patients will be recruited, treated and observed in cohorts of 3.

The patients shall then be followed up at 48 hours post Radiotherapy, 7 days post radiotherapy and 29 days post radiotherapy. With assessment of Physiological parameters, survival status, laboratory testing and imaging performed on follow up at 7 and 29 days.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Low Dose Radiotherapy

Group Type EXPERIMENTAL

Low dose Radiotherapy

Intervention Type RADIATION

External Beam irradiation, single fraction of 0.5Gy, to be delivered within 48 hours of enrolment to study. With field to cover as close to lung edges as AP/PA technique allows.

A further 0.5GY to the thorax given up to 96 hours apart from first fraction is permitted, if a patient had either (a) responded to the first dose but then deteriorated, however remaining better than baseline level or (b) stabilized after first dose but not fully improved.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Low dose Radiotherapy

External Beam irradiation, single fraction of 0.5Gy, to be delivered within 48 hours of enrolment to study. With field to cover as close to lung edges as AP/PA technique allows.

A further 0.5GY to the thorax given up to 96 hours apart from first fraction is permitted, if a patient had either (a) responded to the first dose but then deteriorated, however remaining better than baseline level or (b) stabilized after first dose but not fully improved.

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 50 years.
* Patients have symptoms of COVID-19 infection as per WHO guidelines (e.g. cough, fever, dyspnea, etc.) for under 5 days from hospital admission.
* Patients are hospitalized and meet the criteria for WHO level 5 COVID pneumonia. In addition:
* SpO2 \<94% on Room Air;
* Respiratory rate \>20 Breaths per minute on Room Air.
* Laboratory confirmed COVID-19 infection based on PCR.
* Patients need ward-based oxygen between 28 to 40%.
* Patients able to provide witnessed verbal informed consent.
* Patient is free of other severe medical conditions that would preclude radiotherapy treatment (e.g. severe recent CVA).

Exclusion Criteria

* Pregnant or lactating women.
* Presence of secondary infection with procalcitonin assessment at baseline.
* Patient is generating aerosols e.g. use of CPAP device.
* Hereditary syndromes known to have increase sensitivity to Radiotherapy including, but not limited to, ataxia-telangiectasia, and Njemgen Breakage Syndrome.
* History of prior thoracic radiotherapy.
* Inability to undergo radiotherapy for any reason as determined by the treating medical team.
* Alternative diagnosis for lung compromise unrelated to COVID-19 / deemed more likely than COVID-19 related lung compromise.
* Inability to consent directly.
* If patient has participated in any other COVID-19 therapy study within the last month (4 weeks).
* Pre-existing generalized pulmonary fibrosis.
* Known prior systemic use of the following drugs within the last 6 months: Bleomycin, Carmustine, Methotrexate, Busulfan, Cyclophosphamide, or Amiodarone.
* History of lung lobectomy or pneumonectomy.
* Known history of pulmonary sarcoidosis, Wegener's Granulomatosis, Systemic Lupus Erythematosus, or other autoimmune disease affecting lungs.
* Symptomatic congestive heart failure within the past 6 months including during hospitalization.
* History of recent or current malignancy receiving any cytotoxic chemotherapy or immunotherapy within the past 6 months.
* Bone marrow transplantation.
* Latent tuberculosis.
* Any solid organ transplant (renal, cardiac, liver, lung) requiring immunosuppressive therapy.
* Septic shock and organ dysfunction.
* Severe ARDS P/F ratio ≤100mmHg.

Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No